NUS — Nu Skin Enterprises, Inc.

Is NUS overbought or oversold? Here is the current MarketMoodz read.

Consumer Defensive · Household & Personal Products

Neutral As of October 3, 2026

Nu Skin Enterprises, Inc. (NUS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Consumer Defensive name (Household & Personal Products) last closed at $4.61. The rating moved from Oversold to Neutral on October 2, 2026.

AI analysis

Nu Skin faces meaningful near‑term headwinds stemming from regulatory scrutiny of health and influencer claims, a cyclical direct‑selling model susceptible to distributor activity and reputation risk, and soft demand pressure that has constrained revenue and margins. While recurring consumable products provide some revenue stability, limited visible growth catalysts and balance‑sheet sensitivity leave upside muted absent clear cost restructuring, new-market traction, or resolution of regulatory issues. Short‑term scenarios skew toward continued volatility and downside if enforcement or distributor trends worsen; upside would require demonstrable operational improvement and regained consumer/distributor confidence.

Key factors

  • Persistent regulatory and compliance scrutiny in consumer‑health and labeling that raises potential corrective-advertising and enforcement costs.
  • Direct‑selling business model sensitivity to distributor recruitment/activity and reputational risk from influencer endorsements.
  • Weak recent top‑line traction and margin pressure versus historical levels (soft demand in key markets and promotional pressure).
  • Limited visibility on near‑term revenue growth absent clear new product or channel catalysts; reliance on repeat consumables provides some stability.
  • Macroeconomic risk and risk‑off market tone reducing investor appetite for higher‑beta consumer discretionary / wellness names.
  • Balance‑sheet and liquidity considerations relative to peers (requires ongoing cash generation or cost actions to restore investor confidence).

Risks

  • Escalation of regulatory enforcement, fines, or mandated corrective advertising related to health/labeling claims or influencer activity.
  • Material deterioration in distributor base or direct‑selling recruitment that depresses sales and cash flows.
  • Adverse litigation outcomes or class actions tied to marketing practices or product claims.
  • Slower consumer spending or further global supply‑chain disruption hitting inventory flow and margins.
  • Currency exposure and geopolitical disruptions in international markets could amplify revenue volatility.
  • Potential for reputational shocks from product safety or endorsement controversies that reduce brand equity.

See today's live rating, score and targets

Members see the live hourly rating for NUS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.